Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3548-3551

  Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; LETROZOLE; PAMIDRONIC ACID; SEX HORMONE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; BODY MASS; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; BREAST FEEDING; BREAST HYPERPLASIA; CANCER HORMONE THERAPY; CANCER RISK; CANCER TREATMENT INDUCED BONE LOSS; DATA BASE; DRUG MECHANISM; EDITORIAL; ETHNICITY; FEMALE; HAZARD RATIO; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; IMMUNOCOMPETENT CELL; MICROENVIRONMENT; OBSERVATIONAL STUDY; OSTEOPOROSIS; OVERALL SURVIVAL; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIGNAL TRANSDUCTION; SMOKING; THERAPY EFFECT; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BREAST TUMOR; NOTE; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK;

EID: 77955881211     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.6327     Document Type: Editorial

References (37)

1. National Osteoporosis Foundation: Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 2010, pp 1-36
2. World Health Organization: Prevention and management of osteoporosis - WHO Technical Report Series 921. Geneva, Switzerland, World Health Organization, 2003, pp 1-192
3. Rosen CJ: Clinical practice: Postmenopausal osteoporosis. N Engl J Med 353:595-603, 2005
4. Stevenson JC: Hormone replacement therapy and cardiovascular disease revisited. Menopause Int 15:55-57, 2009
5. Aclasta: Summary of Product Characteristics. http://www.ema.europa.eu/ humandocs/PDFs/EPAR/aclasta/emea-combined-h595en.pdf
6. Bonviva: Summary of Product Characteristics. http://www.ema.europa.eu/ humandocs/PDFs/EPAR/Bonviva/emea-combined-h501en.pdf
7. Boniva: Prescribing Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2006/021858s001lbl.pdf
8. Reclast: Prescribing Information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/021817s004lbl.pdf
9. Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
10. Eidtmann H, Bundred NJ, DeBoer R, et al: The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008
11. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849, 2008
12. Lester JE, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342, 2008
13. Van Poznak C, Hannon RA, Mackey JR, et al: Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28:967-975, 2010
14. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453-475, 2008
15. Coleman RE, Winter MC, Cameron D, et al: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105, 2010
16. Gnant M: Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials. Curr Cancer Drug Targets 9:824-833, 2009
17. Chlebowski RT, Chen Z, Cauley JA, et al: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590, 2010
18. Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581, 2010
19. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 133:571-573, 1889
20. Chen WY: Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab 22:573-585, 2008
21. Cauley JA, Lucas FL, Kuller LH, et al: Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures - Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408, 1996 (Pubitemid 26365846)
22. Chen Z, Arendell L, Aickin M, et al: Hip bone density predicts breast cancer risk independently of Gail score: Results from the Women's Health Initiative. Cancer 113:907-915, 2008
23. Zmuda JM, Cauley JA, Ljung BM, et al: Bone mass and breast cancer risk in older women: Differences by stage at diagnosis. J Natl Cancer Inst 93:930-936, 2001 (Pubitemid 32624650)
24. Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799-802, 2010
25. Diel IJ, Jaschke A, Solomayer EF, et al: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up. Ann Oncol 19:2007-2011, 2008
26. Powles T, Paterson A, McCloskey E, et al: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13, 2006
27. Saarto T, Blomqvist C, Virkkunen P, et al: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17, 2001 (Pubitemid 32063474)
28. Saarto T, Vehmanen L, Virkkunen P, et al: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656, 2004 (Pubitemid 39563937)
29. Kristensen B, Ejlertsen B, Mouridsen HT, et al: Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47:740-746, 2008 (Pubitemid 351878444)
30. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
31. Aft R, Naughton M, Trinkaus K, et al: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial. Lancet Oncol 11:421-428, 2010
32. Lin AY, Park JW, Scott J, et al: Zoledronic acid as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008
33. Rack BK, Jueckstock J, Genss E-M, et al: Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
34. Solomayer EF, Gebauer G, Hirnle P, et al: Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008
35. Ellis GK, Bone HG, Chlebowski R, et al: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882, 2008
36. Stopeck A, Body JJ, Fujiwara Y, et al: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: Results of a randomized phase 3 study. Presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009
37. Bone HG, Bolognese MA, Yuen CK, et al: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149-2157, 2008 (Pubitemid 351831529)